Indole compound and preparation method and application thereof
1. An indole compound, characterized by having a structure represented by formula I:
wherein, X is substituted or unsubstituted alkyl of C1-C8, cycloalkyl of C3-C8 or benzyl; the substituted substituents are: halogen substituted or unsubstituted C1-C3 alkyl, C1-C3 alkoxy, halogen, phenyl or pyridyl, wherein the number of the substituents is 1, 2 or 3;
y is CH3Or H;
z is
2. The compound of claim 1, wherein Z isThe compound has the structure shown in formula II:
wherein, X is substituted or unsubstituted alkyl of C1-C8, cycloalkyl of C3-C8 or benzyl; the substituent is halogen substituted or unsubstituted C1-C3 alkyl, C1-C3 alkoxy, halogen, phenyl or pyridyl, and the number of the substituents is 1, 2 or 3;
y is CH3Or H.
3. The compound of claim 2, wherein X is substituted or unsubstituted C3-C6 alkyl, C3-C6 cycloalkyl, or benzyl; the substituent is methyl, trifluoromethyl, methoxy, fluorine or pyridyl, and the number of the substituent is 1 or 2;
y is CH3Or H.
4. A compound according to claim 3, wherein X is 2-butyl, 2-pentyl, cyclopentyl, benzyl, 3, 5-dimethoxybenzyl, 3, 5-difluorobenzyl, 4-trifluoromethylbenzyl, 1-phenylethyl orPreferably, it is
Y is CH3Or H.
5. The compound of claim 1, wherein Z isThe compound has a structure represented by formula III:
wherein, X is substituted or unsubstituted alkyl of C1-C8, cycloalkyl of C3-C8 or benzyl; the substituent is C1-C3 alkyl, C1-C3 alkoxy, halogen, phenyl or pyridyl, and the number of the substituents is 1, 2 or 3;
y is CH3Or H.
6. The compound of claim 5, wherein X is substituted or unsubstituted C3-C6 alkyl, C3-C6 cycloalkyl, or benzyl; the substituent is methyl, methoxy, fluorine or pyridyl, and the number of the substituent is 1 or 2;
y is CH3Or H.
7. A compound according to claim 6, wherein X is 2-butyl, 2-pentyl, cyclopentyl, benzyl, 3, 5-dimethoxybenzyl, 3, 5-difluorobenzyl, 1-phenylethyl orPreferably, it is
Y is CH3Or H.
8. A compound according to any one of claims 1 to 7, having the structure:
9. a method for synthesizing the compound of claims 1 to 8, comprising the steps of:
1) reacting the compound A with bromide in a solvent under the action of alkali to obtain B;
the alkali is sodium hydride or calcium hydride; the reaction temperature is 0-30 ℃; the molar ratio of the A, the bromide and the alkali is 1 (1-5) to 1-5; the solvent is DMF;
2) reacting the compound B in a solvent under the action of an oxidant to obtain a compound C;
the oxidant is phosphorus oxychloride; the reaction temperature is 0-30 ℃; the molar ratio of the oxidant to the compound B is (4-6) to (3-5); the solvent is DMF;
3) reacting the compound C in a solvent under the action of p-toluenesulfonic acid, p-toluenesulfonyl hydrazide, sulfolane and sodium cyanoborohydride to obtain a compound D;
the reaction temperature is 0-100 ℃; the solvent is DMF;
4) under the action of a palladium catalyst, carrying out coupling reaction on a borate compound and a compound B or a compound D in a solvent;
the palladium catalyst is [1,1' -bis (diphenylphosphino) ferrocene]Any one of palladium dichloride dichloromethane complex, palladium acetate or tetrakis (triphenylphosphine) palladium; the borate ester compound is The solvent for the reaction is a mixed solution of dioxane and water, and the volume ratio of (1-5) to 1; the reaction temperature is 90-110 ℃; the molar ratio of the borate compound to the compound B or D to palladium is (1-2) 1: 0.05; removing a protecting group from the obtained compound in 2M sodium hydroxide solution to obtain a compound shown as a formula I;
the reaction formula is as follows:
10. use of a compound of claims 1-8 in a BRD4 inhibitor, preferably, the BRD4 inhibitor is a medicament for preventing or treating cancer, cancer metastasis, inflammation, cardiovascular disease, immune disease, metabolic disease, or fibrotic disease.
Background
The BRD4 protein is the most important functional protein in bromodomain and super-terminal family protein (BET) family, and contains two bromodomains and one super-terminal domain. BRD4 not only plays a role in transcriptional regulation, but also can control the activation, repair and maintenance of telomeres at DNA damage checkpoints, and plays a role other than transcription. BRD4, as a histone reader, accumulates in highly acetylated and transcriptionally predisposed chromatin regions (including the promoter and ENH) and serves as a nucleation center for large protein complex assembly, promoting RNA PolII activity, stimulating transcription initiation and elongation, a function that is largely dependent on the BD of BRD4 and their ability to recognize acetyl proteins.
BRD4 binds to the hyper-acetylated chromatin region, recruits the Mediator complex, promotes the assembly of large transcriptional regulatory proteins, forms a bridge between SE and the promoter, and is beneficial to stabilizing the binding of RNA PolII.
BRD4 also activates P-TEFb, stimulating the conversion of RNA PolII to active extension.
BETi competes with acetylated residues for binding to the BRD4 bromodomain, releasing BRD4 from chromatin and disrupting the interaction between SE and promoter, reducing RNA-PolII flux and blocking transcription of key oncogenes. BRD4 also plays an important role in DNA Double Strand Break (DSBs) repair. Acetylation of H4 (H4Ac) and phosphorylation of H2AX (γ H2AX) accumulate at the DSB, triggering BRD4 recruitment. BRD4 promotes and stabilizes the interaction of P53 binding protein (53BP1), and 53BP1 in turn acts as an adaptor for DNA repair assembly and activation.
As the most widely characterized BET protein, BRD4 is implicated in a number of human diseases, including cancer inflammation, cardiovascular disease, Central Nervous System (CNS) diseases and Human Immunodeficiency Virus (HIV) infection. BRD4 has become a promising therapeutic target for a variety of diseases.
The BRD4 inhibitor has good application prospect in the pharmaceutical industry, but no drug on the market exists at present, and a high-efficiency BRD4 inhibitor is continuously developed for achieving the purpose of better treatment effect and meeting the market demand.
Disclosure of Invention
The invention aims to provide a high-efficiency BRD4 inhibitor.
The invention provides an indole compound which has a structure shown in a formula I:
wherein, X is substituted or unsubstituted alkyl of C1-C8, substituted or unsubstituted C3-C8 cycloalkyl or substituted or unsubstituted benzyl; the substituted substituents are: halogen substituted or unsubstituted C1-C3 alkyl, C1-C3 alkoxy, halogen, phenyl or pyridyl, wherein the number of the substituents is 1, 2 or 3.
Y is CH3Or H;
z is
Further, Z isThe compound has the structure shown in formula II:
wherein, X is substituted or unsubstituted alkyl of C1-C8, substituted or unsubstituted C3-C8 cycloalkyl or substituted or unsubstituted benzyl; the substituent is halogen substituted or unsubstituted C1-C3 alkyl, C1-C3 alkoxy, halogen, phenyl or pyridyl, and the number of the substituents is 1, 2 or 3;
y is CH3Or H.
Further, X is substituted or unsubstituted alkyl of C3-C6, substituted or unsubstituted cycloalkyl of C3-C6 or substituted or unsubstituted benzyl; the substituent is methyl, trifluoromethyl, methoxy, fluorine or pyridyl, and the number of the substituent is 1 or 2;
y is CH3Or H.
Preferably, X is 2-butyl, 2-pentyl, cyclopentyl, benzyl, 3, 5-dimethoxybenzyl, 3, 5-difluorobenzyl, 4-trifluoromethylbenzyl, 1-phenylethyl orMore preferably
Y is CH3Or H.
Further, Z isThe compound has a structure represented by formula III:
wherein, X is substituted or unsubstituted alkyl of C1-C8, substituted or unsubstituted cycloalkyl of C3-C8 or substituted or unsubstituted benzyl; the substituent is C1-C3 alkyl, C1-C3 alkoxy, halogen, phenyl or pyridyl, and the number of the substituents is 1, 2 or 3;
y is CH3Or H.
Further, X is substituted or unsubstituted C3-C6 alkyl, C3-C6 cycloalkyl or benzyl; the substituent is methyl, methoxy, fluorine or pyridyl, and the number of the substituent is 1 or 2;
y is CH3Or H.
Preferably, X is 2-butyl, 2-pentyl, cyclopentyl, benzyl, 3, 5-dimethoxybenzyl, 3, 5-difluorobenzyl, 1-phenylethyl orMore preferably
Y is CH3Or H.
Still further, the above compound has the following structure:
the invention also provides a synthesis method of the compound, which comprises the following steps:
1) reacting the compound A with bromide in a solvent under the action of alkali to obtain B;
the alkali is sodium hydride or calcium hydride; the reaction temperature is 0-30 ℃; the molar ratio of the A, the bromide and the alkali is 1 (1-5) to 1-5; the solvent is DMF;
2) reacting the compound B in a solvent under the action of an oxidant to obtain a compound C;
the oxidant is phosphorus oxychloride; the reaction temperature is 0-30 ℃; the molar ratio of the oxidant to the compound B is (4-6) to (3-5); the solvent is DMF;
3) reacting the compound C in a solvent under the action of p-toluenesulfonic acid, p-toluenesulfonyl hydrazide, sulfolane and sodium cyanoborohydride to obtain a compound D;
the reaction temperature is 0-100 ℃; the solvent is DMF;
4) under the action of a palladium catalyst, carrying out coupling reaction on a borate compound and a compound B or a compound D in a solvent;
the palladium catalyst is [1,1' -bis (diphenylphosphino) ferrocene]Any one of palladium dichloride dichloromethane complex, palladium acetate or tetrakis (triphenylphosphine) palladium; the borate ester compound is The solvent for the reaction is a mixed solution of dioxane and water, and the volume ratio of (1-5) to 1; the reaction temperature is 90-110 ℃; the molar ratio of the borate compound to the compound B or D to palladium is (1-2) 1: 0.05; removing a protecting group from the obtained compound in 2M sodium hydroxide solution to obtain a compound shown as a formula I;
the reaction formula is as follows:
the invention also provides application of the compound in a BRD4 inhibitor, preferably, the BRD4 inhibitor is a medicament for preventing and treating cancer, cancer metastasis, inflammation, cardiovascular diseases, immune diseases, metabolic diseases or fibrotic diseases.
Experimental results show that the indole compound has excellent inhibitory effect on BRD4, and IC50The BRD4 inhibitor has a minimum of 107 mu M, and has potential application value in treating various diseases.
In the present invention, "substituted" means that 1, 2 or more hydrogen atoms in a molecule are replaced by other different atoms, molecules, groups, including 1, 2 or more substitutions on the same atom or different atom in the molecule.
In the present invention, the minimum value and the maximum value of the carbon atom content in the hydrocarbon group are indicated by a prefix, for example, the alkyl group of C1-C8 or C1-8 refers to the alkyl group of C1, C2, C3, C4, C5, C6, C7, C8, that is, the alkyl group is a straight chain or branched chain having 1-8 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, sec-butyl, pentyl, hexyl, heptyl, octyl, etc. Similarly, the alkoxy of C1-C3 refers to the alkoxy of C1, C2 and C3; the cycloalkyl group having 3, 4,5, 6, 7 or 8 carbon atoms is C3-C8.
In the present invention, halogen means fluorine, chlorine, bromine or iodine; alkyl refers to a hydrocarbon group formed by dropping one hydrogen atom from a branched or branched alkane molecule;benzyl radicalPhenyl refers to a group formed by dropping one hydrogen atom in a benzene molecular structure:the pyridyl group refers to a group formed by dropping one hydrogen atom in the molecular structure of pyridine.
2-butyl group:2-pentyl group:cyclopentyl group:3, 5-dimethoxybenzyl:3, 5-difluorobenzyl:4-trifluoromethylbenzyl group:1-phenylethyl group:
obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Detailed Description
The raw materials and equipment used in the invention are known products and are obtained by purchasing commercial products.
Example 1 preparation of intermediate 6-methyl-4- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) -1-p-toluenesulfonyl-1, 6-dihydro-7H-pyrrolo [2,3-C ] pyridin-7-one
4-bromo-6-methyl-1-p-toluenesulfonyl-1H-pyrrolo [2,3-C ] pyridin-7 (6H) -one (381mg, 1mmol), pinacol diboron (300mg, 1.2mmol), potassium acetate (200mg, 2mmol), and [1,1' -bis (diphenylphosphino) ferrocene ] palladium dichloride dichloromethane complex (40mg, 0.05mmol) were added to a round bottom flask, followed by dioxane (5mL) addition, nitrogen substitution three times, and heating at 100 ℃ for 4 hours. The completion of the reaction was monitored by TLC, and the organic solvent was removed under reduced pressure, diluted with water and extracted with ethyl acetate. The ethyl acetate phase was washed with water and saturated brine, and dried over anhydrous sodium sulfate. The organic solvent was removed under reduced pressure and the solid mixture was dried over silica gel and purified on a 200-300 silica gel column to give the product in 51% yield.
Example 2 preparation of 6-methyl-4- (1- (pentan-2-yl) -1H-indol-6-yl) -1, 6-dihydro-7H-pyrrolo [2,3-c ] pyridin-7-one
Step 1 preparation of intermediate 6-bromo-1- (pentan-2-yl) -1H-indole
Sodium hydride (5.66g, 141.7mmol) was placed in 6-bromoindole (2.31g, 118.1mmol) in DMF (100ml) and stirred in an ice bath for 20 minutes, 2-bromopentane (2.14g, 141.7mmol) was added while maintaining the ice bath, the ice bath was removed and allowed to warm to room temperature naturally overnight, and the TLC check reaction was complete. The reaction solution was diluted with water, extracted with ethyl acetate, the organic phases were combined, washed with water and saturated brine, respectively, and the organic phase was dried over anhydrous sodium sulfate and concentrated in vacuo to give the product in 98% yield.
Step preparation of 26-methyl-4- (1- (pentan-2-yl) -1H-indol-6-yl) -1, 6-dihydro-7H-pyrrolo [2,3-c ] pyridin-7-one
6-methyl-4- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) -1-p-toluenesulfonyl-1, 6-dihydro-7H-pyrrolo [2,3-C ] pyridin-7-one (513.6mg, 1.2mmol), 6-bromo-1- (pentan-2-yl) -1H-indole (266mg, 1mmol), sodium carbonate (381mg, 3.6mmol), and [1,1' -bis (diphenylphosphino) ferrocene ] dichloropalladium dichloromethane complex (40mg, 0.05mmol) were added to a round bottom flask, followed by dioxane (5mL) and water (2mL), replaced with nitrogen three times and heated at 110 ℃ for 4 hours under nitrogen. The completion of the reaction was monitored by TLC, and the organic solvent was removed under reduced pressure, diluted with water and extracted with ethyl acetate. The ethyl acetate phase was washed with water and saturated brine, and dried over anhydrous sodium sulfate. The organic solvent was removed under reduced pressure and the solid mixture was dried over silica gel and purified on a 200-300 silica gel column to give an intermediate. The intermediate product was placed in dioxane (5mL) and aqueous sodium hydroxide (2M, 5mL), heated at 90 ℃ for 2 hours, TLC monitored for completion of the reaction, and the organic solvent was removed under reduced pressure, diluted with water and extracted with ethyl acetate. The ethyl acetate phase was washed with water and saturated brine, respectively, dried over anhydrous sodium sulfate, and concentrated in vacuo to give the product in 41% yield.
1H NMR(400MHz,DMSO)δ12.10(s,1H),7.65(s,1H),7.60(d,J＝8.2Hz,1H),7.49(d,J＝3.2Hz,1H),7.40–7.32(m,2H),7.25(d,J＝8.0Hz,1H),6.55–6.16(m,2H),4.65(d,J＝8.0Hz,1H),3.60-3.65(m,3H),1.83(ddd,J＝14.1,8.6,4.8Hz,2H),1.47(d,J＝6.8Hz,3H),1.29–0.99(m,2H),0.83(t,J＝7.2Hz,3H).
Example 3, 6-methyl-4- (1- (butan-2-yl) -1H-indol-6-yl) -1, 6-dihydro-7H-pyrrolo [2,3-c ] pyridin-7-one
The reaction was carried out in a similar manner to example 2 using 2-bromobutane as starting material to give the title compound in 78% yield.
1H NMR(400MHz,DMSO)δ12.10(s,1H),7.65(s,1H),7.60(d,J＝8.2Hz,1H),7.49(d,J＝3.1Hz,1H),7.35(s,2H),7.25(d,J＝8.2Hz,1H),6.71–6.18(m,2H),4.57(d,J＝6.9Hz,1H),3.59(d,J＝8.5Hz,3H),1.87(dd,J＝13.6,6.6Hz,2H),1.47(d,J＝6.7Hz,3H),1.33–1.11(m,2H),0.75(t,J＝7.2Hz,3H).
Example 4, 6-methyl-4- (1-cyclopentyl) -1H-indol-6-yl) -1, 6-dihydro-7H-pyrrolo [2,3-c ] pyridin-7-one
The reaction was carried out in a similar manner to example 2 using bromocyclopentane as the starting material to give the title compound in 58% yield.
1H NMR(400MHz,DMSO)δ12.10(s,1H),8.33(s,1H),7.69–7.33(m,3H),7.03(d,J＝25.0Hz,2H),6.86(s,1H),6.47(s,1H),4.67(s,1H),3.67(s,3H),1.94(s,2H),1.84–1.53(m,6H).
Example 5, 6-methyl-4- (1- (3, 5-difluorobenzyl) -1H-indol-6-yl) -1, 6-dihydro-7H-pyrrolo [2,3-c ] pyridin-7-one
The reaction was carried out in a similar manner to example 2 using 3, 5-difluorobenzyl bromide as the starting material to give the title compound in 53% yield.
1H NMR(400MHz,DMSO)δ12.10(s,1H),7.93–7.48(m,3H),7.31(s,3H),7.20–6.73(m,3H),6.56(s,1H),6.27(s,1H),5.53(s,2H),3.55-3.60(m,3H).
EXAMPLE 6-methyl-4- (1- (3, 5-dimethoxybenzyl) -1H-indol-6-yl) -1, 6-dihydro-7H-pyrrolo [2,3-c ] pyridin-7-one
The reaction was carried out in a similar manner to example 2 using 3, 5-dimethoxybenzyl bromide as the starting material to give the title compound in 71% yield.
1H NMR(400MHz,DMSO)δ12.08(s,1H),7.83–7.56(m,2H),7.54(d,J＝3.1Hz,1H),7.29(dd,J＝6.5,3.8Hz,2H),7.24(d,J＝8.2Hz,1H),6.51(d,J＝3.0Hz,1H),6.39(dd,J＝8.1,2.0Hz,3H),6.29(d,J＝2.2Hz,1H),5.39(s,2H),3.67(s,5H),3.58(s,3H).
Example 7, 6-methyl-4- (1-benzyl-1H-indol-6-yl) -1, 6-dihydro-7H-pyrrolo [2,3-c ] pyridin-7-one
The procedure of example 2 was repeated in a similar manner using benzyl bromide as the starting material to give the desired compound in 78% yield.
1H NMR(400MHz,DMSO)δ12.06(s,1H),7.62(d,J＝8.2Hz,1H),7.58(s,1H),7.54(d,J＝3.1Hz,1H),7.32-7.40(m,4H),7.24-7.30(m,4H),6.52(d,J＝3.0Hz,1H),6.31–6.07(m,1H),5.48(s,2H),3.58(s,3H).
Example 8, 6-methyl-4- (1- (pyridin-2-ylmethyl) -1H-indol-6-yl) -1, 6-dihydro-7H-pyrrolo [2,3-c ] pyridin-7-one
Starting from 2-bromomethylpyridine, the expected compound is obtained in a yield of 42% by a reaction analogous to example 2.
1H NMR(400MHz,DMSO)δ12.09(s,1H),8.55(d,J＝4.3Hz,1H),7.72(d,J＝1.5Hz,1H),7.67–7.58(m,2H),7.56(d,J＝3.1Hz,1H),7.45–7.16(m,4H),7.03(d,J＝7.8Hz,1H),6.64–6.11(m,2H),5.56(s,2H),3.59(s,3H).
Example 9, 6-methyl-4- (1- (1-phenylmethyl) -1H-indol-6-yl) -1, 6-dihydro-7H-pyrrolo [2,3-c ] pyridin-7-one
Starting from (1-bromoethyl) benzene, the expected compound is obtained in 78% yield by a reaction analogous to example 2.
1H NMR(400MHz,DMSO)δ12.03(s,1H),8.39(s,1H),7.95(s,1H),7.86(s,1H),7.51(s,1H),7.28(d,J＝15.0Hz,4H),7.22(s,1H),7.11(s,1H),6.88(s,1H),6.79(s,1H),6.42(s,1H),5.81(s,1H),3.67(s,3H),1.74(s,3H).
Example 10, 6-methyl-4- (1- (4- (trifluoromethyl) benzyl) -1H-indol-6-yl) -1, 6-dihydro-7H-pyrrolo [2,3-c ] pyridin-7-one
The desired compound was obtained in 78% yield by a similar reaction to example 2 using 4-trifluoromethyl benzyl bromide as the starting material.
1H NMR(400MHz,DMSO)δ12.06(s,1H),7.62(d,J＝8.2Hz,1H),7.58(s,1H),7.32-7.40(m,4H),7.24-7.30(m,4H),6.52(d,J＝3.0Hz,1H),6.31–6.07(m,1H),5.48(s,2H),3.58(s,3H).
Example 11 preparation of 6-methyl-4- (3-methyl-1- (pentan-2-yl) -1H-indol-6-yl) -1, 6-dihydro-7H-pyrrolo [2,3-c ] pyridin-7-one
Step one 6-bromo-1- (pentan-2-yl) -1H-indole-3-aldehyde
Phosphorus oxychloride (0.83g, 5.43mmol) was added to anhydrous DMF (50mL) in a reaction flask under ice bath, stirred for 30 min, the product of step one, example 2, 6-bromo-1- (pentan-2-yl) -1H-indole (1.16g, 4.53mmol) was dissolved in DMF (50mL), added slowly to the reaction flask, and then stirred for 2.5H at room temperature. After the reaction is finished, diluting with cold water, adjusting the pH value to 8 with 2N sodium hydroxide solution, extracting with ethyl acetate, washing the combined organic layer with cold water and brine, drying with anhydrous sodium sulfate, and concentrating in vacuum to obtain a product with the yield of 99%.
Step two 6-bromo-3-methyl-1- (pentan-2-yl) -1H-indole
6-bromo-1- (pentan-2-yl) -1H-indole-3-aldehyde (1.31g, 4.46mmol) was dissolved in DMF and p-toluenesulfonic acid monohydrate, p-toluenesulfonylhydrazide and then sulfolane were added at room temperature followed by warming to 100 ℃ for 1 hour. Cooling the reaction liquid to room temperature, adding sodium cyanoborohydride in batches, heating to 100 ℃ for 2 hours, then cooling to room temperature, and continuing stirring for 16 hours. Diluting the reaction solution with water, extracting with ethyl acetate, combining organic phases, washing with cold water and brine, drying with anhydrous sodium sulfate, concentrating in vacuum, and carrying out column chromatography to obtain the product with the yield of 34%.
Step three 6-methyl-4- (3-methyl-1- (pentan-2-yl) -1H-indol-6-yl) -1, 6-dihydro-7H-pyrrolo [2,3-c ] pyridin-7-one
The reaction was carried out in a similar manner to the second step of example 2 using 6-bromo-3-methyl-1- (pentan-2-yl) -1H-indole as the starting material to give the product in 42% yield.
1H NMR(400MHz,DMSO)δ9.04(s,1H),8.35(s,1H),7.51(s,1H),7.33(s,1H),7.22(d,J＝15.0Hz,2H),6.86(d,J＝1.8Hz,1H),4.46(s,1H),3.67(s,3H),2.34(s,3H),1.55(d,J＝7.0Hz,3H),1.39(d,J＝19.1Hz,3H),1.29–0.99(m,2H),0.89(s,2H).
Example 12, 6-methyl-4- (1- (2-tert-butyl) -3-methyl-1H-indol-6-yl) -1, 6-dihydro-7H-pyrrolo [2,3-c ] pyridin-7-one
The product obtained in step one of example 3 was used as a starting material to obtain a product in a yield of 25% by a similar reaction to example 11.
1H NMR(400MHz,DMSO)δ9.04(s,1H),8.35(s,1H),7.51(s,1H),7.33(s,1H),7.22(d,J＝15.0Hz,2H),6.86(d,J＝1.8Hz,1H),4.46(s,1H),3.67(s,3H),2.34(s,3H),1.55(d,J＝7.0Hz,3H),1.39(d,J＝19.1Hz,3H),0.89(s,2H).
Example 13, 6-methyl-4- (1- (3, 5-difluorobenzyl) -3-methyl-1H-indol-6-yl) -1, 6-dihydro-7H-pyrrolo [2,3-c ] pyridin-7-one
The product obtained in step one of example 5 was used as a starting material to obtain a product in a yield of 25% by a similar reaction to example 11.
1H NMR(400MHz,DMSO)δ12.11(s,1H),7.83–7.53(m,2H),7.38–7.21(m,4H),7.14(t,J＝9.3Hz,1H),6.90(d,J＝6.5Hz,2H),6.29(s,1H),5.47(d,J＝18.2Hz,2H),3.60(s,3H),2.31(s,3H).
Example 14, 6-methyl-4- (1- (benzyl) -3-methyl-1H-indol-6-yl) -1, 6-dihydro-7H-pyrrolo [2,3-c ] pyridin-7-one
The product obtained in step one of example 7 was used as a starting material to obtain a product in a yield of 25% by a similar reaction to example 11.
1H NMR(400MHz,DMSO)δ12.06(s,1H),7.86–7.41(m,1H),7.46–7.05(m,2H),6.60–5.95(m,1H),5.39(s,1H),3.58(s,1H),2.29(s,1H).
Example 15, 6-methyl-4- (1- (pyridin-2-ylmethyl) -3-methyl-1H-indol-6-yl) -1, 6-dihydro-7H-pyrrolo [2,3-c ] pyridin-7-one
The product obtained in step one of example 8 was used as a starting material to obtain a product in a yield of 25% by a similar reaction to example 11.
1H NMR(400MHz,DMSO)δ12.09(s,1H),8.55(d,J＝4.3Hz,1H),7.67–7.58(m,2H),7.56(d,J＝3.1Hz,1H),7.45–7.16(m,4H),7.03(d,J＝7.8Hz,1H),6.64–6.11(m,2H),5.56(s,2H),5.41(s,1H),3.59(s,3H).
Example 16, 3, 5-dimethyl-4- (1- (pentyl-2-yl) -1H-indol-6-yl) isoxazole
The product of step one, example 2, 6-bromo-1- (pentan-2-yl) -1H-indole (266mg, 1mmol) and 3, 5-dimethylisoxazole-4-boronic acid pinacol ester (245mg, 1mmol), sodium carbonate (381mg, 3.6mmol) and [1,1' -bis (diphenylphosphino) ferrocene ] dichloropalladium dichloromethane complex (40mg, 0.05mmol) were charged to a round bottom flask, followed by dioxane (5mL) and water (2mL), replaced with nitrogen three times and heated under nitrogen at 110 ℃ for 4 hours. The completion of the reaction was monitored by TLC, and the organic solvent was removed under reduced pressure, diluted with water and extracted with ethyl acetate. The ethyl acetate phase was washed with water and saturated brine, and dried over anhydrous sodium sulfate. The organic solvent was removed under reduced pressure and the solid mixture was dried over silica gel and purified on a 200-300 silica gel column to give the intermediate in 56% yield.
1H NMR(400MHz,DMSO)δ7.60(d,J＝8.1Hz,1H),7.55–7.40(m,2H),6.98(dd,J＝8.1,1.1Hz,1H),6.50(d,J＝3.1Hz,1H),4.68(dd,J＝14.7,6.4Hz,1H),2.42(s,3H),2.26(s,3H),1.86(ddd,J＝14.3,9.4,5.1Hz,1H),1.81–1.66(m,1H),1.45(d,J＝6.7Hz,3H),1.09-1.07(m,2H),0.82(t,J＝7.3Hz,3H).
Example 17, 3, 5-dimethyl-4- (1- (butyl-2-yl) -1H-indol-6-yl) isoxazole
The product obtained in step one of example 3 was used as a starting material to obtain a product in a yield of 25% by a similar reaction to example 16.
1H NMR(400MHz,DMSO)δ7.60(d,J＝8.1Hz,1H),7.55–7.40(m,2H),6.98(dd,J＝8.1,1.1Hz,1H),6.50(d,J＝3.1Hz,1H),4.68(dd,J＝14.7,6.4Hz,1H),2.42(s,3H),2.26(s,3H),1.86(ddd,J＝14.3,9.4,5.1Hz,1H),1.81–1.66(m,1H),1.45(d,J＝6.7Hz,3H),0.82(t,J＝7.3Hz,3H).
Example 18, 3, 5-dimethyl-4- (cyclopentyl-1H-indol-6-yl) isoxazole
The product obtained in step one of example 4 was used as a starting material to obtain a product in a yield of 25% by a similar reaction to example 16.
1H NMR(400MHz,DMSO)δ7.61(d,J＝8.1Hz,1H),7.56–7.44(m,2H),6.99(d,J＝8.1Hz,1H),6.48(d,J＝3.1Hz,1H),5.05–4.86(m,1H),2.42(s,3H),2.25(s,3H),2.16(dd,J＝15.5,7.9Hz,2H),1.87(d,J＝14.1Hz,4H),1.71(d,J＝4.6Hz,2H).
Example 19, 3, 5-dimethyl-4- (1- (3, 5-difluorobenzyl) -1H-indol-6-yl) isoxazole
The product obtained in the first step of example 5 was used as a starting material to obtain a product in a yield of 25% by a similar reaction to example 16.
1H NMR(400MHz,DMSO)δ7.64(t,J＝5.1Hz,2H),7.49(s,1H),7.13(dd,J＝6.9,4.7Hz,1H),7.01(t,J＝7.4Hz,3H),6.55(d,J＝3.1Hz,1H),5.48(s,2H),2.36(s,3H),2.19(s,3H).
EXAMPLE 20, 3, 5-dimethyl-4- (1- (3, 5-dimethoxybenzyl) -1H-indol-6-yl) isoxazole
The product obtained in step one of example 6 was used as a starting material to obtain a product in a yield of 25% by a similar reaction to example 16.
1H NMR(400MHz,DMSO)δ7.60(dd,J＝17.8,5.6Hz,1H),7.45(s,1H),7.00(dd,J＝8.1,1.3Hz,1H),6.68–6.19(m,2H),5.36(s,1H),3.67(s,2H),2.35(s,1H),2.18(s,1H).
Example 21, 3, 5-dimethyl-4- (1-benzyl-1H-indol-6-yl) isoxazole
The product obtained in the first step of example 7 was used as a starting material to obtain a product in a yield of 25% by a similar reaction to example 16.
1H NMR(400MHz,DMSO)δ7.60(dd,J＝15.1,5.6Hz,1H),7.42(s,1H),7.37–7.11(m,2H),6.99(d,J＝8.1Hz,1H),6.52(d,J＝3.0Hz,1H),5.76(s,1H),5.45(s,1H),2.34(s,1H),2.17(s,1H).
Example 22, 3, 5-dimethyl-4- (1- (pyridin-2-ylmethyl) -1H-indol-6-yl) isoxazole
The product obtained in step one of example 8 was used as a starting material to obtain a product in a yield of 25% by a similar reaction to example 16.
1H NMR(400MHz,DMSO)δ8.61–8.38(m,1H),7.72(td,J＝7.7,1.8Hz,1H),7.63(d,J＝8.1Hz,1H),7.57(d,J＝3.1Hz,1H),7.42(s,1H),7.27(dd,J＝6.8,5.0Hz,1H),7.12(d,J＝7.8Hz,1H),7.00(dd,J＝8.1,1.3Hz,1H),6.53(d,J＝3.1Hz,1H),5.54(s,2H),2.34(s,3H),2.17(s,3H).
Example 23, 3, 5-dimethyl-4- (1- (1-phenylmethyl) -1H-indol-6-yl) isoxazole
The product obtained in the first step of example 9 was used as a starting material to obtain a product in a yield of 25% by a similar reaction to example 16.
1H NMR(400MHz,DMSO)δ7.75(d,J＝3.2Hz,1H),7.61(d,J＝8.1Hz,1H),7.35(s,1H),7.31(dd,J＝7.9,3.1Hz,4H),7.26–7.16(m,1H),6.97(dd,J＝8.1,1.2Hz,1H),6.55(d,J＝3.1Hz,1H),5.87(d,J＝7.1Hz,1H),2.30(s,3H),2.13(s,3H),1.89(d,J＝7.1Hz,3H).
Example 24, 4- (1- (2-butyl) -3-methyl-1H-indol-6-yl) -3, 5-dimethylisoxazole
The product obtained in step two of example 12 was used as a starting material to obtain a product in a yield of 25% by a similar reaction to example 16.
1H NMR(400MHz,DMSO)δ8.14(s,1H),7.46(d,J＝21.3Hz,2H),6.57(s,1H),4.43(s,1H),2.43(s,3H),2.34(s,3H),2.25(s,1H),1.55(d,J＝8.4Hz,3H),1.37(s,10H),0.89(s,1H).
Example 25, 4- (1- (3, 5-difluorobenzyl) -3-methyl-1H-indol-6-yl) -3, 5-dimethylisoxazole
The product obtained in step two of example 13 was used as a starting material to obtain a product in a yield of 25% by a similar reaction to example 16.
1H NMR(400MHz,DMSO)δ7.58(d,J＝8.1Hz,1H),7.40(d,J＝27.2Hz,2H),7.12(t,J＝9.4Hz,1H),7.00(t,J＝8.8Hz,3H),5.40(s,2H),2.36(s,3H),2.29(s,3H),2.19(s,3H).
Example 26, 4- (1-benzyl-3-methyl-1H-indol-6-yl) -3, 5-dimethylisoxazole
The product obtained in step two of example 14 was used as a starting material to obtain a product in a yield of 25% by a similar reaction to example 16.
1H NMR(400MHz,DMSO)δ7.56(d,J＝8.1Hz,1H),7.38(s,1H),7.34–7.17(m,9H),6.98(dd,J＝8.1,1.0Hz,1H),5.37(s,2H),2.34(s,3H),2.28(s,3H),2.17(s,3H).
The beneficial effects of the compounds of the present invention are demonstrated by the following experimental examples.
Experimental example 1 in vitro enzyme inhibition assay
1. Experimental methods
His-tagged BRD4 was cloned, expressed and purified to homogeneity. BRD4 binding and inhibition was assessed by detecting the interaction of biotinylated H4-tetraacetyl peptide (AnaSpec, H4k5/8/12/16(Ac), biotin-labeled) with the target using the alashascreen technique. BRD4(2nM final) was combined with peptide (15nM final) in 50mM HEPES (pH 7.3), 10mM NaCl, 0.25mM TCEP, 0.1% (w/v) BSA, and 0.005% (w/v) Brij-35 in 384-well ProxiPlates, in the presence of compound dilution series in DMSO. After incubation for 20 minutes at 25 degrees celsius at room temperature, the alpha streptavidin donor beads and acceptor beads were added to a final concentration of 5 μ g/mL. After 2 hours of equilibration, plates were read on the Envison instrument and IC calculated using fit50。
2. Results of the experiment
Compounds of the invention and positive control JQ1(JQ1 is a commercially available BET bromodomain inhibitor, acting on BRD4(1/2) and binding to all bromodomains of the BET familyAnd not to bromodomains outside the BET family. JQ1 can inhibit cell proliferation by inducing autophagy. ) IC producing inhibitory activity against BRD450The values are shown in Table 1:
inhibitory Activity of the Compounds of Table 1 on the BRD4 enzyme IC50(μM)。
Examples
BRD4(D1,D2)
Examples
BRD4(D1,D2)
1
578
14
208
2
674
15
2436
3
618
16
>3000
4
347
17
>3000
5
559
18
>3000
6
471
19
>3000
7
107
20
2654
8
544
21
481
9
764
22
>3000
10
784
23
>3000
11
951
24
>3000
12
419
25
>3000
13
514
JQ1
90
In conclusion, the invention provides an indole compound with excellent inhibitory effect on BRD4, IC50The BRD4 inhibitor has a minimum of 107 mu M, and has potential application value in treating various diseases.
